MIAMI - As much as people may celebrate their own weight loss, it is not always healthy. A new study shows that weight loss in older adults is associated with early death and life-limiting conditions.

The first oral GLP-1 medication for weight loss has been approved for use in the U.S. The Wegovy pill, from drugmaker Novo Nordisk, was cleared by the Food and Drug Administration to reduce excess ...

New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that around two thirds of participants of the SURMOUNT-1 trial had only regained 5% ...

With the holidays past and the new year arrived, we look ahead — to losing weight. For some that resolve theoretically involves dieting or gym memberships, but for increasing numbers of overweight ...

Altimmune is developing an anti-obesity drug, Pemvidutide, that shows promising results in targeting fat mass and promoting weight loss. The obesity treatment market is expected to grow exponentially, ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And one ...

UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk In a placebo-controlled phase 2 trial in Chinese ...